Chimerix Inc is a biopharmaceutical company that develops and commercializes oral antivirals. Its compounds include brincidofovir (BCV, CMX001).
Our STA Research today shows that the stock is due for a 98% increase in it’s stock valuation within a 6 to 12 month duration. Yahoo Finance Analyst Report indicates a 27% increase. Our STA Research rating indicates the stock a Buy with Bearish near term sentiment.